Trial Profile
A Randomized, Open-Label, Active-Controlled Study of the Safety, Efficacy, and Pharmacokinetics of Ferumoxytol Compared with Oral Iron for the Treatment of Iron Deficiency Anemia in Pediatric Subjects with Chronic Kidney Disease
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary) ; Ferrous fumarate
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors AMAG Pharmaceuticals
- 20 Dec 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 19 Sep 2016 Status changed from active, no longer recruiting to discontinued as several factors contributed to significant challenges in enrollment and led the Sponsor to discontinue the AMAG-FER-CKD-251 study as designed.
- 15 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record..